Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomericaBMRA -6.28%50 Net Margin % is -132.93% as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Biomerica ranks worse than 81.74% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Biomerica's Net Income for the
three
months ended in Feb. 2026 was $-1.31 Mil. Biomerica's Revenue for the
three
months ended in Feb. 2026 was $0.99 Mil. Therefore, Biomerica's net margin for the quarter that ended in Feb. 2026 was -132.93%.
The historical rank and industry rank for Biomerica's Net Margin % or its related term are showing as below:
BMRA'
s Net Margin % Range Over the Past 10 Years
Min: -133.73 Med: -43.01 Max: -15.69
Current: -96.49
BMRA's Net Margin % is ranked worse than 81.74% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs BMRA: -96.49
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biomerica Net Margin % Related Terms
Biomerica Net Margin % Historical Data
* Premium members only.
The historical data trend for Biomerica's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biomerica's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomerica Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biomerica's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomerica (BMRA) has a Net Margin % of -132.93% as of Feb. 2026. Net margin is the ratio of total net income to net sales. View historical data on Biomerica and its competitors. According to the industry distribution chart, Biomerica ranks #667 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 81.7%.
Is Biomerica's Net Margin % too high?
Biomerica's current Net Margin % is -132.93%. Based on the distribution chart, Biomerica ranks #667 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Net Margin % compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #667 out of 816 companies for Net Margin %. This places Biomerica in the lower half of its industry. The industry median Net Margin % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biomerica and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomerica's current Net Margin % is -132.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current Net Margin % is -132.93%. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biomerica (BMRA), the current Net Margin % is -132.93% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomerica (BMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Biomerica stock appears to be undervalued.
The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18.
GuruFocus considers Biomerica to be Possible Value Trap.
Key valuation signals for BMRA:
Net Margin %: -132.93%
GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score
Get the complete analysis for BMRA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRA has been successfully added to your 
